Dow Down0.02% Nasdaq Up0.07%

Franklin Biotechnology Discovery Adv (FTDZX)

174.03 Up 3.12(1.83%) Nov 24

Profile as of Oct 30, 2014Get Profile for:
Franklin Biotechnology Discovery Adv
Franklin Strategic SeriesOne Franklin ParkwaySan Mateo, CA 94403-1906
Phone: 800-632-2301
Fund Overview 
Fund Family:Franklin Templeton Investments
Net Assets:1.68B
Year-to-Date Return:30.45%
Morningstar Rating:4 stars
Fund Inception Date:Sep 1, 2009
Morningstar Style Box 
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Evan S. McCulloch
Lead Manager since Sep 15, 1997
Mr. McCulloch has been a portfolio manager of the Fund since 1997 and assumed duties of lead portfolio manager of the Fund in 2000. He has primary responsibility for the investments of the Fund. He has final authority over all aspects of the Fund's investment portfolio, including but not limited to, purchases and sales of individual securities, portfolio risk assessment, and the management of daily cash balances in accordance with anticipated cash management requirements. The degree to which he may perform these functions, and the nature of these functions, may change from time to time.
Investment Information 
Min Initial Investment:1,000,000
Min Initial Investment, IRA:N/A
Min Initial Investment, AIP:N/A
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
FTDZX can be purchased from 35 brokerages.

Fund Summary 
The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 15, 2013) : 0.00
Annual Holdings Turnover (Nov 23, 2014) : 48.70%
Average for Category:53.85%
Fees & Expenses 
ExpenseFTDZXCategory Avg
Annual Report Expense Ratio (net):0.80%1.43%
Prospectus Net Expense Ratio:0.80%N/A
Prospectus Gross Expense Ratio:0.80%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:255667
5 Yr Expense Projection*:4441,042
10 Yr Expense Projection*:9902,038
* Per $10,000 invested